Clincosm LogoSign in Get a demo

Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06073756
Collaborator
(none)
106
Enrollment
48
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Condition or Disease Intervention/Treatment Phase
  • Radiation: Echocardiogram

Detailed Description

Vascular complications of DM result from various disorders including metabolic, cellular, and blood disturbances. Excessive production of pro-inflammatory adipokines from adipose tissue, resulting in low-grade chronic inflammation, causing insulin resistance (IR) and type 2 DM [3]. Hematological changes affecting the red blood cells (RBCs), white blood cells (WBCs), platelet function, and the coagulation factors are detected to be associated with DM . It is important to add that, high WBC count, one of the chief components of inflammatory process, sharing to atheroscle-rosis development and cardiovascular diseases (CVD) . Lately, the neutrophil-to-lymphocyte (N/L) and the platelet-to-lymphocyte (P/L) ratios, were offered as markers of inflammation in cardiac diseases, neoplasms and diabetes-related complications . Moreover, high leucocyte counts have been used as diagnostic and prognostic markers in vascular complication of diabetes

Study Design

Study Type:
Observational
Anticipated Enrollment :
106 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2027
Anticipated Study Completion Date :
Dec 1, 2027

Arms and Interventions

Arm Intervention/Treatment
1

Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C <7and ages ranging from ≥18 old.

Radiation: Echocardiogram
Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Other Names:
  • ALB / cr ratio
  • Fundus examination
  • ECG
  • Doppler on lower limbs
  • Nerve conduction
  • Echo

    		•
    2

    Type 2 diabetes mellitus (T2DM) patients with poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old

    Radiation: Echocardiogram
    Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
    Other Names:
  • ALB / cr ratio
  • Fundus examination
  • ECG
  • Doppler on lower limbs
  • Nerve conduction
  • Echo

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio [Basline]

      Measurement of Neutrophils to lymhocyte ratio and platelets to lymhocyte ratio in patients with type 2 DM

    Secondary Outcome Measures

    1. HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications [Basline]

      Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C <7and ages ranging from ≥18 old. And poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old
    Exclusion Criteria:
    • Patients with, type 1 diabetes mellitus

    1. Idiopathic thrombocytopenic purpura,

    2. liver cell failure

    3. Myeloproliferative neoplasm

    4. patients on anticoagulant drugs , anti platelet drugs or on steroids were excluded from the study

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Ammar Ashraf fathy, Ammar Ashraf, Assiut University
    ClinicalTrials.gov Identifier:
    NCT06073756
    Other Study ID Numbers:
    • NLR and PLR and in type 2 DM
    First Posted:
    Oct 10, 2023
    Last Update Posted:
    Oct 10, 2023
    Last Verified:
    Oct 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ammar Ashraf fathy, Ammar Ashraf, Assiut University
    Neutrophils to lymhocyte ratio and platelets to lymhocyte ratio
    Additional relevant MeSH terms:
    Diabetic Angiopathies

    Study Results

    No Results Posted as of Oct 10, 2023